Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Heat shock protein 90 (HSP90) N-terminal domain is a highly conserved region of the HSP90 molecular chaperone that contains the essential ATP-binding pocket [1, 2]. This domain is responsible for the ATPase activity that drives the conformational changes necessary for the chaperone's function in protein folding and stabilization [1, 6, 10]. HSP90 facilitates the maturation of hundreds of "client" proteins, including many oncoproteins involved in cell signaling, cell cycle regulation, and apoptosis [2, 3, 11]. In cancer cells, HSP90 is often overexpressed and hijacked to maintain the stability of mutated or overexpressed signaling proteins, a phenomenon known as oncogene addiction [3, 11]. Therapeutic targeting of the N-terminal domain involves small molecules that competitively bind to the ATP pocket, thereby inhibiting the chaperone cycle [1, 2, 10]. This inhibition leads to the misfolding and subsequent proteasomal degradation of client proteins, resulting in the simultaneous disruption of multiple oncogenic pathways [2, 3, 10, 12]. While potent in preclinical models, N-terminal inhibitors have faced clinical hurdles such as hepatotoxicity, ocular toxicity, and the induction of a pro-survival heat shock response [2, 7, 12, 14].
Competitive inhibition of the ATP-binding pocket in the N-terminal domain [1, 2, 10], preventing the ATPase-driven chaperone cycle [1, 6, 10] and leading to the proteasomal degradation of client proteins [2, 3, 10, 12].
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heat shock protein 90 N-terminal domain (HSP90 NTD) (HSP90 NTD).